West had been CSO and CEO of Advanced Cell Technology , which later changed its name to Ocata Therapeutics and was sold to Astellas Pharma in 2016 .
In 2007 , the company appointed Michael D. West , Ph. D , as chief executive officer .
Michael D. West had been CSO and CEO of Advanced Cell Technology , which later changed its name to Ocata Therapeutics and was sold to Astellas Pharma in 2016 .
In 2007 , the company appointed Michael D. West , Ph. D , as chief executive officer .